Summary. The in-vitro test of rat interstitial cell testosterone secretion and a radioimmunoassay (RIA) were used to explore the nature of the LH released in women in response to LH-RH. The ratio of in-vitro bioactivity to immunoreactivity (B:I) calculated for serum samples collected from hypogonadal women using the standard LER-907 for comparison was 13\m=.\25\m=+-\0\m=.\56.This mean ratio was significantly elevated (P < 0\m=.\02)above that found for normal cyclic women, 9\m=.\48\ m=+-\ 0\m=.\49.After one i.v. injection of 10 \g=m\gLH-RH, 5 hypogonadal and 6 luteal-phase women showed an initial significant drop in the B :I ratio (P < 0\m=.\05and P < 0\m=.\02 respectively) followed by a steady significant rise (P < 0\m=.\03; P < 0\m=.\01 respectively).
Introduction
The use of in-vitro bioassays for human serum luteinizing hormone (LH) has recently increased (Dufau, Beitins, McArthur & Catt, 1976; Graesslin et al, 1976; Romani, Robertson & Diczfalusy, 1977) due to disparities found between LH quantifying techniques using immunoreactivity and those utilizing receptor activation. Serum LH levels measured by in-vitro bioassay are frequently higher than those determined by radio-immunoassay. These differences in the biological and immunological potency of serum LH are more marked in men and in post-menopausal women, and in normal late-follicular and luteal-phase women after sub¬ cutaneous injection of 100 µg LH-RH than in normal cyclic women with no LH-RH stimulation (Dufau et al, 1976) . Changes in the ratio of biologically active : immunologically active LH in the blood could be associated with physiological differences in the rate or nature of LH secretion. Because structural alterations in the LH molecule may affect the biological and antigenic properties of this molecule differently and may arise too rapidly to be observed by infrequent sampling, we have used rapid sampling times, and an in-vitro bioassay and a radioimmunoassay for LH to explore the nature of the LH released in response to low doses of (Yen, VandenBerg, Rebar & Ehara, 1972) .
The bioactivity of plasma LH was determined by the rat interstitial cell testosterone assay as described by Dufau et al (1976) and the immunoreactive LH was measured by a double-antibody radioimmunoassay (RIA) (Yen, Llerna, Pearson & Littell, 1968) . The standard used in the bioassay was the pituitary standard 69/104 which is an ampouled version of LER-907 derived from the same source (Bangham et al, 1973 468-5% and by RIA = 824-8%) in response to the first LH-RH injection, the B:I ratio fell (P < 0-02 when each of the three baseline samples was independently compared with the B:I ratio of the sample 15 min after the first LH-RH injection).
As LH values fell (46-0% by bioassay and 69-0% by RIA), the B:I ratio began to rise; the ratio peaked at the point where immunoreactive LH was back to baseline levels (P < 0-01 when the B:I ratio for the sample 15 min after the first LH-RH injection was compared with that after 105 min). With the second LH-RH injection, LH again rose (total rise = 159-5% by bioassay, 442-9% by RIA) and B:I ratio dramatically fell (P < 0-02 when the B:I ratio for the sample immediately before the second LH-RH injection was compared with that for the sample 15 min after the second LH-RH injection). Serum LH levels then fell (total fall = 38-3% by bioassay and 67-0% by RIA) and the B:I ratio rose (P < 0-02 for comparison of samples 15 min and 105 min after the second LH-RH injection). fig. 2 ).
Discussion
The range in the : I ratio for circulating LH in normal premenopausal and hypogonadal women (Table 1) indicates that separate structural properties of the molecule are being recognized by the LH receptor involved in cell activation and the antibody employed for radioimmunoassay (RIA) . Although the ratios in Table 1 (1980) who used a similar infusion protocol but found no changes in the : I ratio with LH release in men and women.
The : I ratios for plasma LH during the period of the LH surge have been reported to be significantly lower than those throughout the remainder of the cycle (Robertson, Puri, Lindberg & Diczfalusy, 1979) . Since LH rises most rapidly during the LH surge, the lower : I ratio found for plasma samples during the surge is consistent with the decreased : I ratios observed as LH was rapidly rising in the circulation in the present study. Isoelectric focussing has shown that bioactive LH in mid-cycle plasma is physicochemically different from that in post-menopausal plasma (Robertson, Van Damme & Diczfalusy, 1977) , indicating that different forms of LH may be responsible for changes in the : I ratio.
Two possible explanations for the biphasic initial drop followed by a rise in the B:I ratio after a low-dose LH-RH injection are: (1) a metabolic change in the LH molecule after release from the pituitary, which renders it more bioactive and/or less immunoreactive, or (2) 2 or more kinds of LH, one or more with a slower in-vivo clearance rate and an increased : I ratio. It is also possible that differences in the B:I ratio are related to the beta subunit LH reacting with the RIA system but being devoid of biological activity. LH subunits are released with LH in response to LH-RH administration (Hagen & McNeilly, 1975; Rosemberg & Bulat, 1979) . However, the plasma levels of subunits reported by Hagen & McNeilly (1975) Changes in the : I ratio are more likely to occur during the process of gonadotrophin secretion, rather than through alterations in the molecular structure of the circulating hormone (Sharpe, Shahmanesh, Ellwood, Hartog & Brown, 1975; Liu, Ax & Jackson, 1979; Mukhopadhyay, Leidenberger & Lichtenberg, 1979 (Liu et al, 1979; Mukhopadhyay et al, 1979) . This pituitary LH form has been proposed as a possible prohormone for LH (Liu et al, 1979) .
Although there is some evidence that metabolic changes in LH occur after its secretion in man (Leidenberger et al, 1976) and rat (Campbell, 
